Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Pelthos Therapeutics Inc. (PTHS : AMEX)

• Company Description    Pelthos Therapeutics is a biopharmaceutical company. Its lead product includes ZELSUVMI(TM) topical gel. Pelthos Therapeutics, formerly known as Channel Therapeutics Corporation, is based in DURHAM, N.C. Number of Employees: 11

• Price / Volume Information    Yesterday's Closing Price: $26.48 Daily Weekly Monthly 20 Day Moving Average: 157,236 shares Shares Outstanding: 0.65 (millions) Market Capitalization: $17.17 (millions) Beta: 3.63 52 Week High: $30.24 52 Week Low: $4.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 97.61% 90.21% 12 Week 43.91% 21.05% Year To Date 313.11% 286.87%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 4400 Route 9 South Suite 1000 - Freehold,NJ 07728 USA ph: 877-265-8266 fax: - mmoyer@lifesciadvisors.com http://www.channeltherapeutics.com

• General Corporate Information    Officers Francis Knuettel II - Chief Executive Officer and President; Chief Finan Ezra Friedberg - Director Todd Davis - Director Richard Malamut - Director Chia-Lin Simmons - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 171126204 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/12/25 Share - Related Items Shares Outstanding: 0.65 Most Recent Split Date: 7.00 (0.10:1) Beta: 3.63 Market Capitalization: $17.17 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/12/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 41.82% vs. Previous Quarter: 0.00% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - -419.25 12/31/24 - -313.69 Current Ratio 06/30/25 - - 03/31/25 - 0.18 12/31/24 - 0.34 Quick Ratio 06/30/25 - - 03/31/25 - 0.18 12/31/24 - 0.34 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - -6.83 12/31/24 - -4.50 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Capital 06/30/25 - - 03/31/25 - - 12/31/24 - -

Powered by Zacks Investment Research ©